23 completed, 9 terminated, 6 unknown, 2 withdrawn. 42 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 42 | Completed 23, Terminated 9, Unknown 6, Withdrawn 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow Neurotoxicity Syndromes: new trials by email Literature Review of Neurotoxicity Syndromes trials Research Report on Neurotoxicity Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atamparib in Patients With Advanced Solid Tumors atamparib escalation levels, atamparib RP2D - NSCLC Adenocarcinoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Nerviano Medical Sciences (Shanghai) Ltd. | 178 | 2026-03-18 | 2026-07-29 |
| ADC-induced Neurotoxicity Treated With Duloxetine duloxetine - Solid Tumour | Phase 2 | Unknown | Fudan University | 37 | 2024-08-06 | 2024-09-19 |
| Study of the Drug B11-FC (Botulism Treatment) B11-FC, Botulinum neurotoxin type A, Placebo - Botulism | Phase 1 / Phase 2 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 40 | 2024-08-01 | 2024-08-30 |
| Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG® rBV A/B - Botulism | Phase 2 | Completed | California Department of Public Health | 25 | 2024-07-09 | 2026-07-30 |
| AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia AV-101, Placebo - Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Unknown | VistaGen Therapeutics, Inc. | 20 | 2022-08-01 | 2021-05-26 |
| Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia NLX-112, Placebo - Medication-Induced Dyskinesia | Phase 2 | Completed | Neurolixis SAS | 27 | 2021-11-09 | 2024-04-23 |
| Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia CPL500036 - low dose, CPL500036 - high dose, Placebo - Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Completed | Celon Pharma SA | 105 | 2021-11-02 | 2025-03-04 |
| Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy Dipraglurant - Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2 / Phase 3 | Terminated | Addex Pharma S.A. | 17 | 2021-10-25 | 2025-08-06 |
| Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy Dipraglurant, Placebo - Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2 / Phase 3 | Terminated | Addex Pharma S.A. | 25 | 2021-08-06 | 2025-08-06 |
| A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Anakinra, Axicabtagene Ciloleucel - Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | Completed | Marcela V. Maus, M.D.,Ph.D. | 15 | 2020-10-01 | 2025-11-25 |
| o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer Tadalafil 5 mg - Prostate Cancer Metastatic Disease, Chemotherapy Induced Peripheral Neuropathy (CIPN) | Phase 2 | Completed | Tri-Service General Hospital (TSGH) | 90 | 2020-01-05 | 2026-01-12 |
| A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity Defibrotide - DLBCL, Neurotoxicity Syndromes | Phase 2 | Terminated | Jazz Pharmaceuticals | 25 | 2019-10-04 | 2021-12-09 |
| Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG® rBV A/B - Botulism | Phase 2 | Completed | California Department of Public Health | 32 | 2019-03-07 | 2021-10-19 |
| A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment Pitolisant (BF2.649), Placebo - Alcohol Abuse, Nervous System | Phase 2 | Withdrawn | Bioprojet | 2016-10-01 | 2017-01-12 | |
| Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS) tSMS, sham - Dyskinesia, Medication-Induced, Parkinson's Disease | Phase 2 | Completed | Fundación de investigación HM | 50 | 2015-10-01 | 2018-10-11 |
| Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients monosialoganglioside - Neurotoxicity | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 106 | 2015-07-01 | 2015-07-17 |
| Effects of Folic Acid Supplementation on Arsenic Lowering folic acid supplementation - Arsenic Poisoning, Toxic Effect of Arsenic and Its Compounds | Phase 2 | Unknown | Wenzhou Medical University | 450 | 2014-07-01 | 2014-09-10 |
| Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Lorazepam, Placebo, Haloperidol decanoate - Advanced Cancers | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 93 | 2014-01-01 | 2026-07-17 |
| Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease Topiramate, Placebo, Amantadine - Idiopathic Parkinson's Disease, Drug Induced Dyskinesia | Phase 2 | Terminated | Rush University Medical Center | 42 | 2013-03-01 | 2019-04-16 |
| Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid rBV A/B - Botulism | Phase 2 | Completed | California Department of Public Health | 45 | 2013-02-01 | 2017-05-16 |
Showing 20 of 42. Sign in to see all of them.
Dyskinesia, Drug-Induced (10) · Parkinson Disease (8) · Botulism (5) · Dyskinesias (5) · Lymphoma (4) · Peripheral Nervous System Diseases (4) · Carcinoma, Ovarian Epithelial (3) · Ovarian Neoplasms (3) · Akathisia, Drug-Induced (2) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Lymphoma, Large B-Cell, Diffuse (2) · Neuroleptic Malignant Syndrome (2)
Chemically-Induced Disorders (42) · Nervous System Diseases (42) · Poisoning (42) · Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (16) · Neurologic Manifestations (15) · Central Nervous System Diseases (13) · Neoplasms (13) · Basal Ganglia Diseases (11) · Brain Diseases (11) · Drug-Related Side Effects and Adverse Reactions (11) · Movement Disorders (11) · Neoplasms by Histologic Type (9) · Neuromuscular Diseases (9)
Amifostine (3) · Paclitaxel (3) · 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (2) · 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine (2) · Leucovorin (2) · Levetiracetam (2) · Methotrexate (2) · Procarbazine (2) · Radiotherapy (2) · Vincristine (2) · 130-nm albumin-bound paclitaxel (1) · Amantadine (1) · Amifampridine (1) · Bortezomib (1) · Botulinum Toxins, Type A (1)
California Department of Public Health (3) · Addex Pharma S.A. (2) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · University College, London (2) · University of South Florida (2) · Assistance Publique - Hôpitaux de Paris (1) · Bioprojet (1) · Celon Pharma SA (1) · Centre Hospitalier Universitaire, Amiens (1) · City of Hope Medical Center (1) · Columbia University (1) · Fudan University (1) · Fundacion Oncosur (1) · Fundación de investigación HM (1)
United States (20) · France (4) · China (3) · Germany (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Israel (1) · Italy (1) · Poland (1) · Sweden (1) · Taiwan (1)
Adrian Newman-Tancredi, PhD (1) · Antonio Omuro, MD (1) · Arthur Forman, MD (1) · Blanca Cantos, MD (1) · Caicun Zhou, Dr. (1) · Christopher G Goetz, MD (1) · David H. Moore, MD (1) · David Hui, MD (1) · Erick Gamelin, MD (1) · Eva Ciruelos, MD (1) · Firoozeh Sahebi, MD (1) · Gerald Higa, PharmD (1) · Guglielmo Foffani, PhD (1)
PMID 14615449, PMID 24007658, PMID 24355920, PMID 26559255, PMID 28975307, PMID 29475762, PMID 31023863, PMID 31666259, PMID 33750072, PMID 34661903, PMID 37399456, PMID 39928957
U10CA081920 (2), 2005 (1), P30CA033572 (1), R21CA186000 (1)